Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine

Peter Rauko, Ladislav Novotny, Ima Dovinova, Luba Hunakova, Thomas Szekeres, Hiremagalur N. Jayaram

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Benzamide riboside (BR), a new synthetic nucleoside analogue, has demonstrated a potent cytotoxic activity in murine leukemia in vitro. The purpose of the present investigation was to examine the antitumor activity of BR in mice bearing leukemia L1210. The results revealed that BR possesses a potent antitumor activity in vivo. It increases life-span of mice with leukemia. Synergistic cytotoxicity of BR with select DNA damaging agents, cisplatin (cis-Pt) and staurosporine (STP) was examined in MTT chemosensitivity assay, FACS analyses and apoptotic DNA fragmentation on L1210 cells in culture. A simultaneous treatment of leukemia L1210 cells with the combination of BR and STP resulted in synergistic cytotoxicity that correlated with increased apoptotic activity in those cells. On the other hand, treatment of L1210 cells with combination of BR and cis-Pt resulted in antagonistic cytotoxic effect. Finally, to elucidate the synergistic effect of BR and STP in inducing apoptosis, the attention was directed to the activation of cell death processes through various cell cycle signals. This is the first report describing in vivo antitumor activity of BR and its utilization in combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalEuropean Journal of Pharmaceutical Sciences
Issue number4
StatePublished - 2001


  • Apoptosis
  • Benzamide riboside
  • Cisplatin
  • Cytotoxicity
  • Murine leukemia cells
  • Staurosporine

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine'. Together they form a unique fingerprint.

Cite this